Paradoxical exacerbation of chronic plaque psoriasis by sorafenib.

Abstract

Vascular endothelial growth factor (VEGF) antagonists have been investigated as a potential treatment for psoriasis, but there have been reports of VEGF antagonists triggering and/or exacerbating pre-existing psoriasis. We present the case of a 61-year old-man with exacerbation of pre-existing psoriasis after treatment with sorafenib, a small molecule inhibitor of the tyrosine kinase domain of the VEGF receptor, and we review the literature for other published cases of sorafenib-induced or sorafenib-exacerbated psoriasis. Clinicians, including both dermatologists and oncologists, should be aware of this potential side-effect of sorafenib in addition to the other cutaneous side effects reported for this drug.

• Authors: Z Z N Yiu, F R Ali, C E M Griffiths
• Journal: Clinical and experimental dermatology (Clin Exp Dermatol) Vol. 41 Issue 4 Pg. 407-9 (Jun 2016) ISSN: 1365-2230 [Electronic] England
• PMID: 26667599 (Publication Type: Case Reports, Journal Article, Review)
• Copyright: © 2015 British Association of Dermatologists.

Chemical References

• Phenylurea Compounds
• Niacinamide
• Sorafenib

Topics

• Carcinoma, Hepatocellular (drug therapy)
• Humans
• Liver Neoplasms (drug therapy)
• Male
• Middle Aged
• Niacinamide (adverse effects, analogs & derivatives, therapeutic use)
• Phenylurea Compounds (adverse effects, therapeutic use)
• Psoriasis (chemically induced)
• Sorafenib